Biotechnology researchers at SignaBlok have presented promising preclinical data on a novel TREM-1 inhibitor that could potentially transform treatment approaches for pancreatic cancer and other difficult-to-treat solid tumors. The company's experimental drug demonstrated significant capabilities in preventing cancer recurrence and improving patient outcomes in rodent studies.
The research, to be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, revealed that the macrophage-restricted TREM-1 inhibitor shows remarkable potential when administered after standard chemotherapy. Critically, the drug not only improved complete response and survival rates but also reversed immunosuppression and overcame resistance to existing immunotherapies.
Pancreatic cancer remains one of the most challenging malignancies, with a devastating five-year survival rate of merely 13%. The low survival rate underscores the urgent need for innovative therapeutic strategies, making SignaBlok's research particularly significant.
The study's unique approach targets TREM-1, an inflammation amplifier critically involved in multiple disease pathologies. By developing a ligand-independent inhibitory peptide, SignaBlok has potentially opened a new avenue for treating inflammation-associated cancers.
Safety profiles from rodent studies indicate the experimental drug is well-tolerated, suggesting promising translational potential. The research also highlights the company's proprietary SCHOOL technology platform, which enables drug development with potentially reduced risk of failure due to its novel mechanism of action.
While further clinical research is necessary, these preclinical findings represent a potentially transformative approach to treating pancreatic cancer and potentially other hard-to-treat solid tumors. The research will be presented by SignaBlok's President and Principal Investigator, Alexander B. Sigalov, Ph.D., during Poster Session 52 at the AACR Annual Meeting.
